| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
CAR-T in B-Cell Lymphomas: The Past, Present, and Future
|
Al-Juhaishi, Taha
|
|
|
22 |
4 |
p. e261-e268
|
artikel
|
| 2 |
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
|
Bennani, N. Nora
|
|
|
22 |
4 |
p. e250-e260
|
artikel
|
| 3 |
Characterization of Primary and Secondary Cutaneous B-Cell Lymphomas: A Population-Based Study of 4758 Patients
|
Leary, Daniel O’
|
|
|
22 |
4 |
p. e269-e278
|
artikel
|
| 4 |
Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study
|
Ocio, Enrique M.
|
|
|
22 |
4 |
p. e241-e249
|
artikel
|
| 5 |
Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes
|
Fang, Kun
|
|
|
22 |
4 |
p. 224-235
|
artikel
|
| 6 |
Corrigendum to ‘MPN-395: Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S367–S368]
|
|
|
|
22 |
4 |
p. 276
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
22 |
4 |
p. A1-A2
|
artikel
|
| 8 |
Erratum to ‘Potential New Therapeutic Approaches for Myelofibrosis’ [Clinical Lymphoma Myeloma & Leukemia 21S1 (2021) S130-S133 / EXABS-189-MPN]
|
|
|
|
22 |
4 |
p. 277
|
artikel
|
| 9 |
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma
|
Caro, Jessica
|
|
|
22 |
4 |
p. e279-e284
|
artikel
|
| 10 |
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience
|
Ambinder, Alexander
|
|
|
22 |
4 |
p. 260-269
|
artikel
|
| 11 |
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies
|
Garcia-Manero, Guillermo
|
|
|
22 |
4 |
p. 236-250
|
artikel
|
| 12 |
Outcomes of HTLV-1 Carriers with Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Matched Cohort Study
|
Valcarcel, Bryan
|
|
|
22 |
4 |
p. 251-259
|
artikel
|
| 13 |
Prevalence and Clinical Outcome of FMS-Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor—Acute Myeloid Leukemia: Systematic Review and Meta-Analysis
|
Srinivasan, Shyam
|
|
|
22 |
4 |
p. e221-e232
|
artikel
|
| 14 |
Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma
|
Tilch, Marie-Kristin
|
|
|
22 |
4 |
p. 270-275
|
artikel
|
| 15 |
Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML
|
Lalayanni, Chrysavgi
|
|
|
22 |
4 |
p. e233-e240
|
artikel
|
| 16 |
SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?
|
Thompson, Philip A.
|
|
|
22 |
4 |
p. 205-209
|
artikel
|
| 17 |
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
|
Chifotides, Helen T.
|
|
|
22 |
4 |
p. 210-223
|
artikel
|
| 18 |
Table of Contents
|
|
|
|
22 |
4 |
p. A3-A4
|
artikel
|
Tijdschrift beschrijving